Qingyu Luo

15PUBLICATIONS
38CO-AUTHORS
Molecular targetsLiquid biopsiesTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 02, 2026
Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP.

|Mar 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

Ran Xu, Gongwei Wu, Siobhan Rice

|Feb 24, 2026
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.

Yabing Nan, Kunyu Wang, Menghan Hu

|Nov 24, 2025
IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer.

Yabing Nan, Sophie O'keefe, Xiadi He

|Mar 19, 2025
PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target.

Qingyu Luo, Amanda L Fortune, Andrew A Lane

|May 08, 2024
Targetable leukaemia dependency on noncanonical PI3Kγ signalling.

Qingyu Luo, Evangeline G Raulston, Miguel A Prado

Pageof 3

Frequent Collaborators

8 joint publications

Xiaowei Wu

7 joint publications

Zhihua Liu

5 joint publications

Yabing Nan

5 joint publications

Andrew A Lane